Discontinuing adalimumab increases relapse rates in patients with juvenile idiopathic arthritis (JIA)–associated uveitis. However, patients can regain inflammation control after resuming the treatment ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback